Urinary metabolomics analysis identifies key biomarkers of different stages of nonalcoholic fatty liver disease

Table 2 Laboratory test results in the three groups of study of participants (mean ± SD)

Group	NASH	NAFLD	Healthy group
HbA1C (%)	5.51 ± 0.58b	5.8 ± 0.62b	4.83 ± 0.47
FBG (mmpl/L)	5.31 ± 0.69	5.4 ± 1.05	5.25 ± 0.33
HDL (mmpl/L)	1.2 ± 0.36	1.28 ± 0.3	1.33 ± 0.37
LDL (mmpl/L)	3.57 ± 0.88b	3.53 ± 0.77b	1.64 ± 0.95
TG (mmpl/L)	2.62 ± 1.4b	2.39 ± 1.64b	1.32 ± 0.41
TC (mmpl/L)	5.37 ± 0.98b	5.3 ± 0.77b	4.32 ± 0.83
FFA (mmpl/L)	0.58 ± 0.25	0.5 ± 0.24	0.44 ± 0.05
ALT (U/L)	100.66 ± 48.4bd	28.9 ± 10.76	27.36 ± 9.76
AST (U/L)	49.68 ± 23.1bd	27.17 ± 12.74	26.41 ± 13.05
GGT (U/L)	75.26 ± 53.1bd	40.25 ± 23.66	27.39 ± 12.04
ALP (U/L)	78.5 ± 33.31	73.43 ± 17.05	79.1 ± 16.02
TBil (μmol/L)	16.42 ± 6.24b	16.63 ± 7.04b	8.99 ± 1.92
DBil (μmol/L)	4.07 ± 2.18	3.7 ± 1.72	3.05 ± 1.34
B ultrasound examination	2.51 ± 0.55ac	1.67 ± 0.48a	0 ± 0

^aP < 0.05,

^bP < 0.01 vs the healthy group;

^c < 0.05,

^dP < 0.01 vs the NAFLD group. NASH: Non-alcoholic steatohepatitis; NAFLD: Non-alcoholic fatty liver disease; HbA1c: Glycosylated hemoglobin; FBG: Fasting blood glucose; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; TG: Triglycerides; TC: Total cholesterol; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: Gamma-glutamyl transferase; Tbil: Total bilirubin; Dbil: Direct bilirubin.